Advanced glycation end products, diabetes, and the brain.

14:07 EDT 21st September 2014 | BioPortfolio

Summary of "Advanced glycation end products, diabetes, and the brain."

No Summary Available

Affiliation

Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157 lcoker@wakehealth.edu.

Journal Details

This article was published in the following journal.

Name: Neurology
ISSN: 1526-632X
Pages: 1326-7

Links

PubMed Articles [17280 Associated PubMed Articles listed on BioPortfolio]

Osseous wound repair under inhibition of the axis of advanced glycation end-products and the advanced glycation end-products receptor.

Blockade of advanced glycation end-products (AGE) is able to reduce diabetic complications and control periodontitis. This study aimed to determine whether the application of aminoguanidine (AG), an A...

Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.

The pathogenesis of diabetic peripheral neuropathy remains uncertain and nonenzymatic glycoxidation is one of the contributing mechanisms. The aim of this study was to assess the respective relationsh...

Receptor for Advanced Glycation End Products (RAGEs) and Experimental Diabetic Neuropathy. Diabetes 2008;57:1002-1017. DOI: 10.2337/db07-0339.

Association Between Endogenous Secretory Receptor for Advanced Glycation-end Products (esRAGE) and Carotid Intima-media Thickness in Type 2 Diabetes.

Advanced glycation end products (AGEs) contribute to vascular complications in type 2 diabetes (T2DM). Endogenous secretory receptor for advanced glycation end products (esRAGE) may inhibit the pathol...

Update of Retraction--Blockade of Receptor for Advanced Glycation End Products in a Model of Type 1 Diabetic Leukoencephalopathy. Diabetes. 19 November 2012 Epub ahead of print. DOI: 10.2337/db12-0317.

Clinical Trials [6505 Associated Clinical Trials listed on BioPortfolio]

Dietary Advanced Glycation End-Products and Insulin Resistance in Overweight and Obese Humans

We hypothesize that reduction in dietary advance glycation endproducts (AGE) intake will increase insulin sensitivity and normalise insulin secretion in overweight and obese individuals th...

Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes

The purpose of the study is to determine whether there are differences in postprandial endothelial function following a high-AGE(Advanced Glycation End-products) meal vs. a low-AGE meal. W...

Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus

An AGE-rich diet can induce after 2-6 weeks persistent increases in mediators linked to vascular dysfunction (e.g. TNFα, VCAM-1) in people with type 2 diabetes mellitus (T2DM). Benfotiami...

The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure

Several lines of evidence have suggested that Advanced Glycation End-products (AGEs) play a role in the development and progression of heart failure. The AGE-crosslink breaker Alagebrium (...

Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy

The purpose of this study is to determine whether oral sevelamer carbonate binds advanced glycation end products (AGEs) in the gastrointestinal (GI) tract of patients with diabetic nephrop...

Medical and Biotech [MESH] Definitions

Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus.

Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).

The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Advanced technology that is costly, requires highly skilled personnel, and is unique in its particular application. Includes innovative, specialized medical/surgical procedures as well as advanced diagnostic and therapeutic equipment.

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Nephrology - kidney function
Latest News Clinical Trials Research Drugs Reports Corporate
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...

Alzheimer's Disease
Latest News Clinical Trials Research Drugs Reports Corporate
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Advertisement